Compared to in the in vitro T cell experiments, in the clinical samples, pathway activity scores varied more between patients, reflecting the heterogeneity of the analyzed breast cancer patient group that consisted of four ER/PR-positive luminal patients, one ER/PR/HER2-positive patient, and five triple-negative patients (Table 3, Figure S1) [19]. Here, ERBB2 is linked to breast cancer.